Drug news
Jakafi (Incyte/Novartis) is FDA approved for Myelofibrosis
The FDA on 16 November 2011, approved Jakafi(ruxolitinib),from Incyte/Novartis, the first drug approved to specifically treat patients with the bone marrow disease Myelofibrosis. Jakafi is an inhibitor of JAK 1 and 2 (Janus Associated Kinase) that are involved in regulating blood and immunological functioning. The decision was based on two pivotal trials called COMFORT-1 and COMFORT-2.
115 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.